Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer.
The prognostic significance of serum level of SCC and CA19-9 (i.e. sr-SCC and sr-CA19-9) and tumor expression of SCC and CA19-9 (i.e. im-SCC and im-CA19-9) were investigated in patients undergoing radiation therapy for cervical cancer. A total of 103 patients comprising 95 squamous cell carcinomas, 3 adenosquamous cell carcinomas and 5 adenocarcinomas, were studied. The tumor expression of SCC and CA19-9 were determined immunohistochemically. The positivity of the patients with abnormal sr-SCC levels for squamous cell carcinoma, adenosquamous cell carcinoma and adenocarcinoma were 87.7%, 50.0% and 40.0%, respectively The 5-year-survival rates of sr-SCC positive and negative patients were 71.1% and 100%, respectively (P > 0.1). The survival rates of im-SCC positive and negative patients were 70.0% and 80.7%, respectively (P > 0.1). The positivity of patients with im-CA19-9 in squamous cell carcinoma, adenosquamous cell carcinoma, im-CA19-9 adenocarcinoma were 29.1%, 66.6%, and 100%, respectively. The 5-year-survival rates of sr-CA19-9 positive patients was 62.5%, poorer than the 77.6% of negative ones (P < 0.1). The survival rate of im-CA19-9 expression positive patients was 92.0%, significantly better than the 70.7% in negative patients (P < 0.05). Although the sr-SCC level just at the end of radiation therapy was not correlated with local control, re-elevation of the SCC was highly associated with early relapse. These results suggested that follow-up of patients by periodical serum examination for these tumor markers is highly useful for the early detection of tumor relapse.
Abe
A
A
Division of Radiation Medicine, National Institute of Radiological Sciences, Chiba, Japan.
Nakano
T
T
Morita
S
S
Oka
K
K
D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism; D018395:CA-19-9 Antigen / Q000097:blood / Q000378:metabolism*; D018196:Carcinoma, Adenosquamous / Q000378:metabolism / Q000401:mortality / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000401:mortality / Q000532:radiotherapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000378:metabolism; D015843:Serpins; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000532:radiotherapy*
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D015843:Serpins; C051072:squamous cell carcinoma-related antigen